Optiver Holding
TRDA icon

Optiver Holding’s Entrada Therapeutics TRDA Stock Holding History

Optiver Holding’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.72K Sell
234
-24
-9% -$230 ﹤0.01% 2354
2026
Q1 		$3.26K Sell
258
-88
-25% -$1.01K ﹤0.01% 1619
2025
Q4 		$3.56K Hold
346
– – ﹤0.01% 1628
2025
Q3 		$2.01K Buy
+346
New +$2.02K ﹤0.01% 2385

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MC
Merck & Co Rahway, New Jersey $526M AUM 175.27% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return

Optiver Holding's TRDA Position: Q2 2026 in Review

Optiver Holding reduced its Entrada Therapeutics (TRDA) stake by 9.3% in Q2 2026, selling an estimated $230 and leaving 234 shares worth $1.72K. The position accounts for ﹤0.01% of the portfolio, ranked #2354.

Optiver Holding first reported a position in TRDA in Q3 2025 and has held it in 4 quarters since. The position peaked at $3.56K in Q4 2025. 128 funds tracked by Wall St. Rank hold TRDA as of Q2 2026.

  • Optiver Holding held 234 shares of Entrada Therapeutics worth $1.72K as of Q2 2026.
  • Optiver Holding sold 24 Entrada Therapeutics shares in Q2 2026, an estimated $230.
  • Entrada Therapeutics made up ﹤0.01% of Optiver Holding's portfolio in Q2 2026, its #2354 holding.
  • Optiver Holding first reported a position in Entrada Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Optiver Holding's Entrada Therapeutics position peaked at $3.56K in Q4 2025.
  • 128 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.